Thomas Jefferson University

Edward Hartsough

TitleAssoc Prof CHP
InstitutionThomas Jefferson University
DepartmentNursing - Undergraduate
Address233 S. 10th Street
Philadelphia PA 19107
Phone2155037592
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Cavallo MR, Yo JC, Gallant KC, Cunanan CJ, Amirfallah A, Daniali M, Sanders AB, Aplin AE, Pribitkin EA, Hartsough EJ. Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma. Cell Death Discov. 2024 Apr 15; 10(1):175. PMID: 38622136.
      Citations:    
    2. Hartsough E, Shelke RRJ, Amraei R, Aryan Z, Lotfollahzadeh S, Rahimi N. PRMT4-mediated arginine methylation promotes tyrosine phosphorylation of VEGFR-2 and regulates filopodia protrusions. iScience. 2022 Aug 19; 25(8):104736. PMID: 35942094.
      Citations:    
    3. Baqai U, Purwin TJ, Bechtel N, Chua V, Han A, Hartsough EJ, Kuznetsoff JN, Harbour JW, Aplin AE. Multi-omics profiling shows BAP1 loss is associated with upregulated cell adhesion molecules in uveal melanoma. Mol Cancer Res. 2022 Apr 15. PMID: 35426938.
      Citations:    
    4. Ciraku L, Moeller RA, Esquea EM, Gocal WA, Hartsough EJ, Simone NL, Jackson JG, Reginato MJ. An Ex Vivo Brain Slice Model to Study and Target Breast Cancer Brain Metastatic Tumor Growth. J Vis Exp. 2021 09 22; (175). PMID: 34633392.
      Citations:    
    5. Smart JA, Oleksak JE, Hartsough EJ. Cell Adhesion Molecules in Plasticity and Metastasis. Mol Cancer Res. 2021 Jan; 19(1):25-37. PMID: 33004622.
      Citations:    
    6. Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, Berger AC, Hartsough EJ, Rodeck U, Alnemri ES, Aplin AE. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov. 2019 Dec 03. PMID: 31796433.
      Citations:    
    7. Erkes DA, Field CO, Capparelli C, Tiago M, Purwin TJ, Chervoneva I, Berger AC, Hartsough EJ, Villanueva J, Aplin AE. The next generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner. Pigment Cell Melanoma Res. 2019 May 07. PMID: 31063649.
      Citations:    
    8. Hartsough EJ, Weiss MB, Heilman SA, Purwin TJ, Kugel CH, Rosenbaum SR, Erkes DA, Tiago M, HooKim K, Chervoneva I, Aplin AE. CADM1 is a TWIST1-regulated suppressor of invasion and survival. Cell Death Dis. 2019 Mar 25; 10(4):281. PMID: 30911007.
      Citations:    
    9. Vido MJ, Le K, Hartsough EJ, Aplin AE. BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. Cell Rep. 2018 Nov 06; 25(6):1501-1510.e3. PMID: 30404005.
      Citations:    
    10. Hartsough EJ, Kugel CH, Vido MJ, Berger AC, Purwin TJ, Goldberg A, Davies MA, Schiewer MJ, Knudsen KE, Bollag G, Aplin AE. Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo. Mol Cancer Ther. 2018 Jan; 17(1):84-95. PMID: 29133617.
      Citations:    
    11. Hartsough EJ, Vido MJ. aC IN, aC OUT-that's what it's all about. Pigment Cell Melanoma Res. 2017 Mar; 30(2):177-178. PMID: 27801548.
      Citations:    
    12. Hartsough EJ, Aplin AE. Of Mice and Melanoma: PDX System for Modeling Personalized Medicine. Clin Cancer Res. 2016 Apr 1; 22(7):1550-2. PMID: 26842234.
      Citations:    
    13. Maghsoudlou A, Meyer RD, Rezazadeh K, Arafa E, Pudney J, Hartsough E, Rahimi N. RNF121 Inhibits Angiogenic Growth Factor Signaling by Restricting Cell Surface Expression of VEGFR-2. Traffic. 2016 Mar; 17(3):289-300. PMID: 26602861; PMCID: PMC4767591.
      Citations:    
    14. Arafa E, Bondzie PA, Rezazadeh K, Meyer RD, Hartsough E, Henderson JM, Schwartz JH, Chitalia V, Rahimi N. TMIGD1 is a novel adhesion molecule that protects epithelial cells from oxidative cell injury. Am J Pathol. 2015 Oct; 185(10):2757-67. PMID: 26342724; PMCID: PMC4607757.
      Citations:    
    15. Srinivasan S, Chitalia V, Meyer RD, Hartsough E, Mehta M, Harrold I, Anderson N, Feng H, Smith LE, Jiang Y, Costello CE, Rahimi N. Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis. Angiogenesis. 2015 Oct; 18(4):449-62. PMID: 26059764; PMCID: PMC4600037.
      Citations:    
    16. Kugel CH, Hartsough EJ, Davies MA, Setiady YY, Aplin AE. Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor. Cancer Res. 2014 Aug 1; 74(15):4122-32. PMID: 25035390.
      Citations:    
    17. Hartsough EJ, Basile KJ, Aplin AE. Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant-Expressing Melanoma. Mol Cancer Res. 2014 May; 12(5):795-802. PMID: 24520098.
      Citations:    
    18. Basile KJ, Le K, Hartsough EJ, Aplin AE. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res. 2014 May; 27(3):479-84. PMID: 24422853.
      Citations:    
    19. Hartsough EJ, Meyer RD, Chitalia V, Jiang Y, Marquez VE, Zhdanova IV, Weinberg J, Costello CE, Rahimi N. Lysine methylation promotes VEGFR-2 activation and angiogenesis. Sci Signal. 2013 Dec 03; 6(304):ra104. PMID: 24300896; PMCID: PMC4108444.
      Citations:    
    20. Basile KJ, Abel EV, Dadpey N, Hartsough EJ, Fortina P, Aplin AE. In Vivo MAPK Reporting Reveals the Heterogeneity in Tumoral Selection of Resistance to RAF Inhibitors. Cancer Res. 2013 Dec 1; 73(23):7101-10. PMID: 24121492.
      Citations:    
    21. Hartsough E, Shao Y, Aplin AE. Resistance to RAF Inhibitors Revisited. J Invest Dermatol. 2014 Feb; 134(2):319-25. PMID: 24108405.
      Citations:    
    22. Hartsough EJ, Aplin AE. A STATement on Vemurafenib-Resistant Melanoma. J Invest Dermatol. 2013 Aug; 133(8):1928-9. PMID: 23856932.
      Citations:    
    23. Rahimi N, Rezazadeh K, Mahoney JE, Hartsough E, Meyer RD. Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesis. Mol Biol Cell. 2012 May; 23(9):1646-56. PMID: 22419821; PMCID: PMC3338432.
      Citations:    
    Hartsough's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (63)
    Explore
    _
    Co-Authors (12)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _